COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat

Nicholas A. Kaufman, Jason E. Beare, Arlene A. Tan, Michael P. Vitek, Suzanne E. McKenna, Michael R. Hoane

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

COG1410, a small, novel ApoE-mimetic peptide derived from the receptor binding region of apolipoprotein E (ApoE), has been classified as anti-inflammatory in nature and improves motor, sensorimotor, and cognitive dysfunction following cortical contusion injury (CCI). In order to further examine COG1410's preclinical efficacy on cognitive recovery, the present study evaluated COG1410 following moderate fluid percussion injury (FPI). Animals were prepared with a moderate, unilateral FPI over the hippocampus. Following FPI, animals received a regimen of five doses of COG1410 or vehicle at 2 and 4. h (1.0. mg/kg, i.v.) followed by additional doses administered 24, 48, and 72. h (1.0. mg/kg, i.p.). Prior to injury, animals were trained for 4 days (4 trials/day) in the Morris water maze (MWM) and then tested for retrograde amnesia on post-FPI day 11 and then on a working memory task on day 18. Testing for motor dysfunction on the tapered balanced beam began on day 2 post-FPI. Administration of this regimen of COG1410 significantly improved retention of memory in the retrograde amnesia test compared to vehicle post-FPI. However, COG1410 did not significantly improve acquisition of working memory in the MWM. Motor dysfunction on the tapered beam post-FPI was improved in the COG1410-treated group compared to vehicle treatment. Cortical lesion analysis revealed that the COG1410-treated animals demonstrated significantly less tissue loss compared to vehicle-treated animals. The results of this study suggest that COG1410 significantly limited the behavioral dysfunction and tissue loss associated with FPI and demonstrated continued preclinical efficacy for TBI.

Original languageEnglish (US)
Pages (from-to)395-401
Number of pages7
JournalBehavioural Brain Research
Volume214
Issue number2
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

Percussion
Apolipoproteins E
Peptides
Wounds and Injuries
Retrograde Amnesia
Short-Term Memory
COG1410
Peptide Receptors
Water
Hippocampus
Anti-Inflammatory Agents

Keywords

  • Amnesia
  • FPI
  • Recovery of function
  • Therapy
  • Traumatic brain injury
  • Treatment

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat. / Kaufman, Nicholas A.; Beare, Jason E.; Tan, Arlene A.; Vitek, Michael P.; McKenna, Suzanne E.; Hoane, Michael R.

In: Behavioural Brain Research, Vol. 214, No. 2, 01.12.2010, p. 395-401.

Research output: Contribution to journalArticle

Kaufman, Nicholas A. ; Beare, Jason E. ; Tan, Arlene A. ; Vitek, Michael P. ; McKenna, Suzanne E. ; Hoane, Michael R. / COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat. In: Behavioural Brain Research. 2010 ; Vol. 214, No. 2. pp. 395-401.
@article{26d1ea0710ab48fb8a156388c9ab8ffd,
title = "COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat",
abstract = "COG1410, a small, novel ApoE-mimetic peptide derived from the receptor binding region of apolipoprotein E (ApoE), has been classified as anti-inflammatory in nature and improves motor, sensorimotor, and cognitive dysfunction following cortical contusion injury (CCI). In order to further examine COG1410's preclinical efficacy on cognitive recovery, the present study evaluated COG1410 following moderate fluid percussion injury (FPI). Animals were prepared with a moderate, unilateral FPI over the hippocampus. Following FPI, animals received a regimen of five doses of COG1410 or vehicle at 2 and 4. h (1.0. mg/kg, i.v.) followed by additional doses administered 24, 48, and 72. h (1.0. mg/kg, i.p.). Prior to injury, animals were trained for 4 days (4 trials/day) in the Morris water maze (MWM) and then tested for retrograde amnesia on post-FPI day 11 and then on a working memory task on day 18. Testing for motor dysfunction on the tapered balanced beam began on day 2 post-FPI. Administration of this regimen of COG1410 significantly improved retention of memory in the retrograde amnesia test compared to vehicle post-FPI. However, COG1410 did not significantly improve acquisition of working memory in the MWM. Motor dysfunction on the tapered beam post-FPI was improved in the COG1410-treated group compared to vehicle treatment. Cortical lesion analysis revealed that the COG1410-treated animals demonstrated significantly less tissue loss compared to vehicle-treated animals. The results of this study suggest that COG1410 significantly limited the behavioral dysfunction and tissue loss associated with FPI and demonstrated continued preclinical efficacy for TBI.",
keywords = "Amnesia, FPI, Recovery of function, Therapy, Traumatic brain injury, Treatment",
author = "Kaufman, {Nicholas A.} and Beare, {Jason E.} and Tan, {Arlene A.} and Vitek, {Michael P.} and McKenna, {Suzanne E.} and Hoane, {Michael R.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.bbr.2010.06.017",
language = "English (US)",
volume = "214",
pages = "395--401",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat

AU - Kaufman, Nicholas A.

AU - Beare, Jason E.

AU - Tan, Arlene A.

AU - Vitek, Michael P.

AU - McKenna, Suzanne E.

AU - Hoane, Michael R.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - COG1410, a small, novel ApoE-mimetic peptide derived from the receptor binding region of apolipoprotein E (ApoE), has been classified as anti-inflammatory in nature and improves motor, sensorimotor, and cognitive dysfunction following cortical contusion injury (CCI). In order to further examine COG1410's preclinical efficacy on cognitive recovery, the present study evaluated COG1410 following moderate fluid percussion injury (FPI). Animals were prepared with a moderate, unilateral FPI over the hippocampus. Following FPI, animals received a regimen of five doses of COG1410 or vehicle at 2 and 4. h (1.0. mg/kg, i.v.) followed by additional doses administered 24, 48, and 72. h (1.0. mg/kg, i.p.). Prior to injury, animals were trained for 4 days (4 trials/day) in the Morris water maze (MWM) and then tested for retrograde amnesia on post-FPI day 11 and then on a working memory task on day 18. Testing for motor dysfunction on the tapered balanced beam began on day 2 post-FPI. Administration of this regimen of COG1410 significantly improved retention of memory in the retrograde amnesia test compared to vehicle post-FPI. However, COG1410 did not significantly improve acquisition of working memory in the MWM. Motor dysfunction on the tapered beam post-FPI was improved in the COG1410-treated group compared to vehicle treatment. Cortical lesion analysis revealed that the COG1410-treated animals demonstrated significantly less tissue loss compared to vehicle-treated animals. The results of this study suggest that COG1410 significantly limited the behavioral dysfunction and tissue loss associated with FPI and demonstrated continued preclinical efficacy for TBI.

AB - COG1410, a small, novel ApoE-mimetic peptide derived from the receptor binding region of apolipoprotein E (ApoE), has been classified as anti-inflammatory in nature and improves motor, sensorimotor, and cognitive dysfunction following cortical contusion injury (CCI). In order to further examine COG1410's preclinical efficacy on cognitive recovery, the present study evaluated COG1410 following moderate fluid percussion injury (FPI). Animals were prepared with a moderate, unilateral FPI over the hippocampus. Following FPI, animals received a regimen of five doses of COG1410 or vehicle at 2 and 4. h (1.0. mg/kg, i.v.) followed by additional doses administered 24, 48, and 72. h (1.0. mg/kg, i.p.). Prior to injury, animals were trained for 4 days (4 trials/day) in the Morris water maze (MWM) and then tested for retrograde amnesia on post-FPI day 11 and then on a working memory task on day 18. Testing for motor dysfunction on the tapered balanced beam began on day 2 post-FPI. Administration of this regimen of COG1410 significantly improved retention of memory in the retrograde amnesia test compared to vehicle post-FPI. However, COG1410 did not significantly improve acquisition of working memory in the MWM. Motor dysfunction on the tapered beam post-FPI was improved in the COG1410-treated group compared to vehicle treatment. Cortical lesion analysis revealed that the COG1410-treated animals demonstrated significantly less tissue loss compared to vehicle-treated animals. The results of this study suggest that COG1410 significantly limited the behavioral dysfunction and tissue loss associated with FPI and demonstrated continued preclinical efficacy for TBI.

KW - Amnesia

KW - FPI

KW - Recovery of function

KW - Therapy

KW - Traumatic brain injury

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77955275113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955275113&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2010.06.017

DO - 10.1016/j.bbr.2010.06.017

M3 - Article

VL - 214

SP - 395

EP - 401

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 2

ER -